Biotech News
Filter News
Found 694,817 articles
-
Danaher Schedules Third Quarter 2021 Earnings Conference Call
9/21/2021
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
-
Whistleblowers Erika Cheung and Tyler Shultz discussed their experiences at Theranos during the recent 2022 AACC Annual Scientific Meeting & Clinical Lab Expo. -
Vela Diagnostics Supports COVID-19 Surveillance Efforts in Kenya
8/3/2022
Vela Diagnostics has announced its appointment by the National Public Health Laboratory of Kenya as their supplier for SARS-CoV-2 genotyping tests, with funding from The Global Fund.
-
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)
8/3/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced promising three-month stability data on a new formulation of RLF-100®.
-
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
8/3/2022
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine, ReCOV from the Food and Drug Administration of the Philippines.
-
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
8/3/2022
Ipsen announced that the Phase III RESILIENT trial did not meet its primary endpoint of overall survival compared to topotecan.
-
Pixium Vision announces regulatory approval of remote rehabilitation system for patients in clinical trials
8/3/2022
Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the approval of the remote rehabilitation system for patients enrolled in the PRIMAvera pivotal trial and the French Feasibility Study in atrophic dry age-related macular degeneration.
-
Axonics® Announces Pricing of Public Offering of Common Stock - Aug 03, 2022
8/3/2022
Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that it priced its previously announced underwritten public offering of 1,750,000 shares of its common stock.
-
Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock
8/3/2022
Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share, representing a premium to the closing price of $19.50 per share on August 2, 2022.
-
Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development
8/3/2022
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the appointment of Dr.
-
Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022
8/3/2022
Burning Rock Biotech Limited, a company focusing on the application of next generation sequencing technology in the field of precision oncology, announced that it will hold its annual general meeting on September 8, 2022 at 10:00 a.m. at the Company’s Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai.
-
Cardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
8/3/2022
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with vascular and coronary artery disease, today reported financial results for its fourth quarter and full year, ended June 30, 2022.
-
IDRx aims to create highly selective and aligned drug combinations to stop key tumor escape mechanisms that will support prolonged and durable responses to therapy. -
According to two recent studies, 10 to 30% of people with COVID-19 reported at least one persistent symptom up to six months after infection, which qualifies as Long COVID. -
AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer. -
The exact implications of the paxalisib disappointment are still unclear, though it is highly likely that the candidate will be dropped from the GBM AGILE umbrella trial. -
The annual Alzheimer’s Association International Conference (AAIC) is running from July 31-August 4 at the San Diego Convention Center and online. Here are some of the highlights presented so far.
-
BioSpace sat down with Katy Powell, a psychiatric mental health nurse practitioner in Portland, Oregon, to discuss the relative risks and benefits associated with psychedelic-assisted therapy.
-
The FDA has placed a clinical hold on Beam Therapeutics' leukemia/lymphoma therapy and has lifted the hold on Celyad's CAR-T candidate for colorectal cancer. -
Waters Corporation (NYSE: WAT) Reports Second Quarter 2022 Financial Results
8/2/2022
Sales of $714 million grew 5% as reported and 10% in constant currency Continued strong momentum as instrument sales grew 12% in constant currency, with double-digit growth across LC, MS and TA product lines Broad-based performance across all end-markets and major geographies, led by mid-teens growth in the U.S.